ARTICLE SUMMARY:
February's most-read articles: Aktiia's clinical-grade wrist wearable can accurately measure blood pressure 24/7; Backed by Deerfield Management, newly private Endologix hopes to regain its footing in AAA repair; BTIG's Ryan Zimmerman opines on the current state of medtech stocks; Optellum's AI-based technology helps clinicians determine if small nodules on a CT image are likely to be cancerous; SyMap's map-and ablate RDN technology.
The top five MedTech Strategist February articles.
Subscribers, click through to read the full articles. Non-subscribers, take advantage of our free trial offer.
#1: Aktiia: Wrist Wearable Delivers Seamless, 24/7 Blood Pressure Monitoring
Start-up Aktiia has developed the first clinical-grade PPG-based wrist wearable that can accurately measure blood pressure in the background throughout the day or night, bringing an unprecedented level of data collection, and potential insights, to the hypertension field..
#2: Endologix: Can Privatization Save This Company?
Already on the ropes as the result of a deal that went wrong, Endologix was saddled with a mountain of debt when the pandemic hit, all but squashing any hopes of pulling itself out of its downward spiral. The only solution: taking the public company private, which it did with the help of Deerfield Management.
#3: Lung Cancer: AI Leads the Way to a Faster and Safer Diagnosis
Optellum’s Virtual Nodule Clinic, the only FDA-cleared AI-enabled decision support system of its kind, predicts with high accuracy the likelihood that a lung nodule found upon imaging is cancerous or benign and thus helps clinicians expeditiously determine the next best step for patients. That’s only the first application for the company, which, in collaboration with many stakeholders, plans to offer analytics that improve every step of the lung cancer care pathway.
#4: Tracking the Pullback in Medtech Stocks
Medtech stocks are down roughly 20% so far this year, slightly more than the S&P, jolted, as are other industries, by uncertainties over COVID-19 and inflation. Drivers of medical device stocks this year center on companies’ top-line growth, propelled by market share and/or revenue gains, according to BTIG Managing Director Ryan Zimmerman.
#5: SyMap Targets Renal Denervation With a Unique Map-and-Ablate Technology
SyMap Medical is developing a selective map-and-ablate technology that has the potential to substantially improve outcomes following renal denervation for treatment-resistant hypertension.